Silver Book Fact
The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.
Romley J, Sanchez Y, Penrod J, Goldman D, et al. Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2011.1301